The purpose of this study is to find out if there is a benefit to reducing systolic blood pressure (SBP) in a more intensive way (keeping SBP less than 140 mmHg) compared with the standard way (keeping SBP less than 180 mmHg). This study is using an FDA approved drug called Nicardipine hydrochloride that is routinely used in treatment of patients with intracerebral hemorrhage. IV Nicardipine is a drug that reduces high blood pressure. While reduction of SBP to 140 mmHg may potentially benefit subjects, it is also unknown whether such a reduction is worse for patients. A patient will have an equal chance of being in either group, and the decision will be made randomly through a computer system.
- Randomized within 4.5 hours of symptom onset
- Need clinical signs consistent with the diagnosis of stroke
- INR value < 1.5
- ICH is due to previously known neoplasms, AVM, or aneurysms
- Known sensitivity to Nicardipine
- Current pregnancy
Number of research visits: There will be a baseline visit which is considered when a patient arrives at the hospital. While a patient is in the hospital, there will be assessments done at 24 hours, 48 hours, 72 hours, and on Day 7 or discharge (whichever comes first). There will be a telephone follow-up (20-30 minutes) on Day 30 and a follow-up visit (30 minutes) on Day 90 in the outpatient clinic.
Length of participation: 90 days
Number of blood collections: 4
Volume of blood collected: 1-2 tablespoons per draw
Frequency of blood pressure measurements: every 15-20 minutes while on study drug
Number of CT scans: 2
Number of EKGs